forest-dwelling Anopheles leucosphyrus mosquitoes, extending across Southeast Asia from Indonesia, the Philippines, and southern China to Bangladesh and eastern India, with human infection reported in many of these countries [5] .
Plasmodium knowlesi can cause severe and fatal disease [2, 3, [6] [7] [8] . The only previous prospective study of knowlesi malaria characterized 10 cases of quinine-treated severe malaria in a district hospital, with 2 deaths [3] . In a retrospective study at Queen Elizabeth Hospital (QEH), a tertiary referral hospital in Sabah, Malaysia, 22 of 56 (39%) patients had severe knowlesi malaria, and 6 (27%) died [7] . In the QEH study, artemisinin-based therapy was associated with faster parasite clearance in uncomplicated and severe knowlesi malaria compared with chloroquine and quinine [7] . As a result, policy changes were instituted in QEH catchment districts for all Plasmodium infections, including early tertiaryhospital referral for severe and/or high-parasitemia infections, and prereferral intravenous artesunate for severe malaria. Following these changes, we conducted a prospective study at QEH to compare risk factors, clinical spectrum, and outcome of severe disease from knowlesi, falciparum, and vivax malaria.
METHODS

Study Site and Referral System
QEH, the largest adult hospital in Sabah, serves as the referral center for the West Coast and Kudat divisions, comprising 6 district hospitals (0.6-3 hours' drive from QEH) and a population of 1.14 million. QEH has modern intensive care facilities for invasive ventilation and renal replacement therapy. From 2010, in response to ongoing malaria deaths in Sabah [7, 8] , new guidelines were implemented, including tertiary-hospital referral for patients with a thick blood film reported as "4 + " (>10 parasites/high-power microscopy field) or clinical suspicion of severe malaria. Treatment was to commence pretransfer, including intravenous artesunate for all severe malaria, or 1 of 2 nationally available oral artemisinin combination therapies (ACTs; artemether-lumefantrine or artesunatemefloquine) for nonsevere knowlesi and falciparum malaria; pretreatment blood films accompanied patients. Local health clinics within the Kota Kinabalu area were required to admit all malaria patients to QEH, with treatment commenced on arrival. Patients were hospitalized until blood smears were negative on 2 consecutive days.
Subjects
All patients admitted to QEH with a microscopic diagnosis of malaria from September 2010 to October 2011 were assessed for eligibility. Consecutive nonpregnant patients ≥12 years old were prospectively enrolled in this comparative clinicalpathophysiological study if they were within 18 hours of commencing malaria treatment, had no major comorbidities, and had not previously been enrolled. Patients with mixed-species infection or parasite-negative polymerase chain reaction (PCR) results were retrospectively excluded. Written informed consent was provided by patients or relatives. Approvals were obtained from the Ethics Committees of the Malaysian Ministry of Health and Menzies School of Health Research.
Study Procedures
Standardized data forms recorded epidemiological, clinical, and baseline laboratory (including prereferral) results. Treatment followed hospital guidelines: artemether-lumefantrine for uncomplicated falciparum and knowlesi malaria; chloroquine + primaquine or ACT for uncomplicated vivax malaria; Figure 1 . Flowchart showing patient enrollment and exclusions in a prospective comparative study of knowlesi, falciparum, and vivax malaria. Abbreviations: P., Plasmodium; PCR, polymerase chain reaction. Patients were assessed daily, including blood films and automated cell counts. Parasite and fever clearance times were defined as the first of 2 consecutive days with a negative blood film and temperature ≤37.5°C, respectively.
Laboratory Procedures
Parasitemia was reported as parasites per 200 leukocytes or 1000 erythrocytes and converted to parasites per microliter. When pretreatment slides were unavailable (6%), referringhospital microscopy was used and the "1+ to 4 + " grade converted into parasites per microliter using relevant median parasite densities. Hematology, biochemistry, blood cultures (where possible), acid-base parameters, and lactate (by bedside blood analysis; iSTAT System) were obtained on admission. Parasite species were identified by PCR, as previously described [11, 12] .
Statistical Analysis
Data were analyzed using Stata software, version 10. 
RESULTS
Baseline Characteristics
In total, 295 patients with PCR-confirmed Plasmodium monoinfection were enrolled ( Figure 1 , Table 1 ), with P. knowlesi the most common species (n = 130; 44%; Table 1 ). Most (n = 86; 66%) knowlesi malaria patients were referred from district hospitals, most commonly Kudat (n = 39; 30%). In contrast, 61% and 51% of patients with falciparum and vivax malaria, respectively, were referred from QEH emergency department or local primary care clinics (Table 1) . Knowlesi malaria patients were older than those with other malaria species (Table 1) ; this difference remained significant after excluding patients referred from district hospitals (median age, 35, 28, and 23 years for knowlesi, falciparum, and vivax malaria, respectively, after exclusion of referred patients, P = .005). Females were older than males among patients with knowlesi (median age, 54 vs 43 years, P = .011) and falciparum (median age, 29 vs 25 years, P = .145), but not vivax malaria.
Nearly all patients with knowlesi and falciparum malaria reported forest or plantation exposure (Table 1) . A greater proportion of P. falciparum patients lived in or near forested areas; however, P. knowlesi patients were more likely to have Day of hemoglobin nadir Day of platelet count nadir Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; NA, not assessed; P., Plasmodium; SD, standard deviation. a P value for proportion of all P. knowlesi patients with parasite count >100 000/µL (14%) versus proportion of all P. falciparum patients with parasite count >100 000/µL (7%) = 0.107.
*Remains significant (P < .05) after adjusting for age and parasite count, using linear or logistic regression for continuous or categorical variables, respectively.
seen a monkey in the preceding month (Table 1 ). Among P. knowlesi patients, 27 of 57 (47%) aged ≥50 years were farmers or plantation workers compared with 26 of 73 (36%) <50 years (P = .176). Median fever duration was 5 days for all malaria species, with minimal differences in clinical characteristics (Table 1) .
Laboratory Investigations
Comparing baseline laboratory investigations (Table 2) , patients with nonsevere knowlesi malaria had lower parasitemia than those with nonsevere falciparum (P < .001), but not vivax malaria (P = .951). Moderate anemia (hemoglobin nadir <10 g/dL) was common in all species, occurring in 36 (28%), 24 (20%), and 10 (23%) patients with knowlesi, falciparum, and vivax malaria, respectively (P = .326). Thrombocytopenia ( platelet count <150 × 10 3 platelets/µL) occurred in all but 1 patient with knowlesi malaria, a 49-year-old splenectomized woman (nadir 260 × 10 3 platelets/µL). Thrombocytopenia was also absent in another splenectomized patient with nonsevere knowlesi malaria who was excluded (antimalarials for >18 hours), but did occur in a splenectomized patient with severe knowlesi malaria (nadir 27 × 10 3 platelets/µL). Platelet counts recovered quickly, with nadir occurring by day 1 in all knowlesi patients.
Severe Knowlesi Malaria
Thirty-eight (29%) knowlesi malaria patients had severe disease (Tables 3 and 4 ), compared to 13 (11%) with falciparum malaria (P < .001) and 7 (16%) with vivax malaria (P = .111) ( Table 5) . Excluding district referrals, 7 of 44 (16%) and 5 of 75 (7%) patients had severe knowlesi and falciparum malaria, respectively (P = .124). Among severe knowlesi patients, 36 (95%) met severity criteria on admission, and 2 (5%) after admission ( patients 18 and 24, Table 4 ). Thirteen patients had 1 severity criterion, 14 had 2 criteria, and 11 had ≥3 criteria. The commonest complications included hyperparasitemia (n = 18, 47%), and jaundice with either renal impairment or parasitemia >20 000 parasites/µL (n = 20, 53%). Only 3 (8%) patients with hyperparasitemia, 1 with creatinine of 173 µmol/L, did not meet other severity criteria. Respiratory distress was common (n = 14, 37%); however, only 2 patients had acute respiratory distress syndrome (ARDS; partial pressure of arterial oxygen:fraction of inspired oxygen < 200 mm Hg) and neither required mechanical ventilation. Hypotension occurred in 13 (34%) patients. Preantibiotic blood cultures, taken in 24 severe cases (including 10 with hypotension), were all negative. AKI occurred in 9 (24%) patients, with 2 requiring acute hemodialysis but none requiring long-term renal replacement therapy. Severe anemia occurred in 2 patients, both with AKI, and an additional 5 were transfused for hemoglobin 7.0-7.8 g/dL. Two patients had significant abnormal bleeding; 1 with bleeding gastric ulceration and 1 with severe epistaxis. The latter patient, with prior idiopathic thrombocytopenic purpura and platelet count 122 × 10 3 platelets/L 6 weeks before admission, had a platelet nadir of 6 × 10 3 platelets/L, the lowest in the study, but recovered rapidly (373 × 10 3 platelets/L by day 8)
without platelet transfusion. No patient had cerebral malaria, although 3 had confusion and agitation, with 2 requiring sedation.
Predictors of Severe Malaria
Severe knowlesi malaria occurred in 27 of 57 (47%) patients aged ≥50 years compared with 11 of 73 (15%) aged <50 years (P < .001). However, using logistic regression, only parasite count and schizontemia >10% independently predicted severe malaria, after adjusting for age and excluding hyperparasitemia as a severity criterion ( Table 6 ). The risk of severe knowlesi malaria increased 11-fold and 28-fold with parasitemias >20 000 parasites/µL and >100 000 parasites/µL, respectively ( Table 7) . The sensitivity and specificity for predicting severe disease using these thresholds were 75% and 79%, and 47% and 97%, respectively (Table 7) , and the area under the ROC No significant (P < .05) differences in severity criteria were demonstrated between species, except for hyperparasitemia.
Abbreviations: IQR, interquartile range; P., Plasmodium. a Hyperparasitemia was defined as >100 000 parasites/µL for P. knowlesi and >10% parasitemia for P. falciparum. b With parasite count >20 000 parasites/µL (for P. knowlesi and P. vivax) or >100 000 parasites/µL (for P. falciparum), and/or creatinine level >132 µmol/L. *P < .0001 for P. knowlesi versus P. falciparum. Figure) . In vivax malaria, increasing age, but not parasitemia, was associated with severe disease, while in falciparum only parasitemia predicted severity. In multiple logistic regression controlling for referral (Table 6 ), P. knowlesi was associated with a 3-fold greater risk of severity than P. falciparum (P = .020). P. knowlesi parasite count was associated with age (ρ = 0.37, P < .001), with median parasitemia higher in those ≥50 years (17 834 parasites/µL) versus <50 years (5430 parasites/µL, P = .004). This association was not seen with falciparum or vivax malaria. Plasmodium knowlesi parasitemia was higher among farmers and plantation workers compared with other occupations (median [interquartile range], 18 740 [4833-61 778] vs 4900 [1610-21 700] parasites/µL, P = .001), remaining significant after controlling for age (P = .014), and with no difference in fever duration.
Associations between parasitemia and laboratory variables, including platelet nadir, neutrophil count, bilirubin level, and lactate level, were stronger in P. knowlesi than in other species (Supplementary Table) . Adjusting for age, knowlesi parasitemia was also associated with jaundice, respiratory distress (Table 8) , and abdominal pain (odds ratio, 1.25 [log increase], P = .026). No association occurred between P. knowlesi parasitemia and fever duration. Controlling for age and parasitemia, patients with severe knowlesi malaria had higher neutrophil counts than those with nonsevere disease (Table 2) ; neutrophil count was associated with creatinine (P = .012) and development of respiratory distress (P = .014).
Response to Treatment
Nearly all (119/130, 92%) patients with knowlesi malaria were treated with oral ACT (artemether-lumefantrine = 109; artesunate-mefloquine = 10), with ≥1 dose of intravenous artesunate also given to 36 of 38 (95%) and 39 of 92 (42%) patients with severe and nonsevere knowlesi malaria, respectively. Fifteen (12%) received concurrent empirical antibiotics. Eleven (8%) patients with nonsevere knowlesi malaria received chloroquine with or without primaquine, including 7 misdiagnosed by microscopy as having P. vivax. All but 2 patients with falciparum malaria received oral ACT; all falciparum patients with severe malaria and 55 of 109 (50%) with nonsevere malaria received ≥1 dose of intravenous artesunate. Five patients with severe vivax malaria received intravenous artesunate. Median parasite clearance time (PCT) for all species was 2 days, with 55 (42%), 34 (28%), and 19 (44%) patients with knowlesi, falciparum, and vivax malaria, respectively, being smear-negative by day 1 (P = .032). Two knowlesi patients had a PCT >3 days, both with severe malaria, including 1 splenectomized patient with a PCT of 9 days. Median fever clearance time was 1 day in knowlesi and vivax malaria and 2 days in falciparum malaria; median duration of hospitalization was 3 days for each species. No deaths occurred. Twenty-three (18%) knowlesi malaria patients were followed up during days 26-41, with no recurrences identified. One patient treated with artemether-lumefantrine was readmitted on day 42 with recurrent knowlesi malaria.
DISCUSSION
Plasmodium knowlesi was the commonest cause of severe malaria at QEH, and was associated with a 3-fold greater risk of severity than P. falciparum. Referral criteria for all species were identical, and the species difference in severity risk remained after adjusting for district referral. Parasite biomass was the major independent risk factor for severe knowlesi malaria, indicating the importance of early diagnosis and rapidly parasiticidal treatment given its 24-hour replication cycle. This study demonstrates excellent early efficacy of intravenous artesunate and ACT for severe and uncomplicated knowlesi malaria, respectively, with standardized early referral and standardized (including prereferral) use of intravenous artesunate and oral ACT likely contributing to the very low case-fatality rate.
The proportion of P. knowlesi cases with severe disease, both before (29%) and after (16%) exclusion of district hospital referrals, is similar to those previously reported (39% retrospectively at QEH [7] and 10% at a district hospital [3] ). However, in contrast to previously reported case-fatality rates of 2% (district hospital) [3] and 11% (referral hospital) [7] , no deaths occurred in our study. In previous reports, most knowlesi patients were treated with chloroquine for uncomplicated malaria and intravenous quinine for severe malaria [2, 3, 6, 7, 13] . Abbreviations: CI, confidence interval; OR, odds ratio. a Three patients with knowlesi malaria and hyperparasitemia as a sole severity criterion were considered nonsevere for this analysis.
b All 7 patients with severe vivax malaria were male; this analysis assumes 1 female has severe vivax malaria.
While chloroquine is efficacious for uncomplicated knowlesi malaria [14] , in a retrospective study parasite clearance was faster with artemether-lumefantrine and artesunate compared with chloroquine and quinine, respectively, with fewer deaths with artesunate than quinine [7] . The low case-fatality rate in this study is not due to more liberal severe malaria criteria. We used stricter criteria for severe knowlesi malaria than those previously used [3] , based on modified WHO 2010 criteria for severe falciparum malaria [9, 10] . Furthermore, deaths from severe knowlesi malaria continued to occur at hospitals in Sabah during 2010-2011 where intravenous artesunate was delayed or not given [8] .
In this study >80% of patients with P. knowlesi parasitemia >100 000 parasites/µL met other severity criteria, supporting the use of this cutoff as a P. knowlesi severity criterion for research purposes and mandating intravenous artesunate. The choice of parasitemia threshold to guide a clinical recommendation for the use of intravenous artesunate below this cutoff is less clear; however, in settings where other (including laboratory) severity criteria cannot be reliably assessed, a conservative cutoff of >20 000 parasites/µL may be appropriate.
Consistent with previous reports [1, 3] , knowlesi patients were older than those with falciparum or vivax malaria. Although older patients with knowlesi malaria were at greater risk of severe disease, this association was explained by the strong correlation between age and parasite count. A greater risk of hyperparasitemia among older patients has also been reported with falciparum malaria [15] .
The lower median parasitemia in nonsevere knowlesi malaria relative to nonsevere P. falciparum indicates a lower fever threshold with P. knowlesi than with P. falciparum, suggesting a greater inflammatory response per parasitized red a Three patients with hyperparasitemia as a sole severity criterion, and 3 patients with bilirubin >43 µmol/L plus parasite count >20 000/µL as a sole severity criterion, were considered nonsevere for this analysis.
Abbreviations: CI, confidence interval; OR, odds ratio; ROC, receiver operating characteristic. Abbreviations: CI, confidence interval; OR, odds ratio. a With parasite count >20 000 parasites/µL (P. knowlesi and P. vivax) or >100 000 parasites/µL (P. falciparum), and/or creatinine level >132 µmol/L.
b Remains significant (P < .05) after adjusting for age.
cell, as seen with P. vivax [16, 17] . In keeping with this, neutrophil count correlated with P. knowlesi parasitemia, and was greater in severe disease. In total, 84 cases of severe knowlesi malaria have been reported: 38 in this series and 46 in 6 previous reports [2, 3, [6] [7] [8] 13 ]. There has been no case of knowlesi-associated coma. Coma has previously been reported in up to half of Asian adults with severe falciparum malaria [18, 19] , involving microvascular sequestration of parasitized erythrocytes [20, 21] , ICAM-1-mediated cytoadherence [21] to brain endothelial cells, and reduced red cell deformability. Although P. knowlesi-infected erythrocytes have been shown to bind to ICAM-1 in vitro [22] , the single P. knowlesi autopsy report did not detect ICAM-1 on brain endothelium, despite demonstrating cerebral parasite accumulation [6] . Red cell agglutination and sludging underlie fatal knowlesi malaria in monkey models [23, 24] . Different microvascular pathogenic mechanisms between P. knowlesi and P. falciparum seem likely.
Although ARDS occurred in 10 of 22 (45%) patients with severe knowlesi malaria in the retrospective QEH series [7] , it was rare in this prospective study, occurring in only 2 patients with neither requiring mechanical ventilation. This may reflect earlier use of artesunate and faster parasite clearance. Milder respiratory distress (hypoxemia without ARDS) was more common, occurring in approximately 30% of patients with severe malaria; the association with parasitemia and neutrophilia suggests parasite-induced inflammatory lung injury.
Thrombocytopenia is near-universal in knowlesi malaria [1, 3, 7] ; however, the mechanism is unknown. The absence of thrombocytopenia in 2 asplenic knowlesi malaria patients contrasts with reports of thrombocytopenia in splenectomized patients with falciparum malaria [25] [26] [27] [28] , suggesting differences in splenic pathophysiology between species.
As previously reported [3, 7, 13] , AKI was common in severe knowlesi malaria. The mechanisms are unknown. Creatinine was associated with parasitemia and neutrophil count. In the single autopsy report of fatal knowlesi malaria, acute tubular necrosis was seen, as well as numerous parasitized erythrocytes within glomerular capillaries. As in falciparum AKI [29] , both parasite biomass and inflammation are likely important.
Plasmodium vivax was also associated with severe malaria in a significant proportion of patients (16%), supporting the now large body of evidence documenting severe complications from this species [30] [31] [32] [33] [34] [35] [36] . Complications of P. vivax included hypotension, jaundice, respiratory distress, and multiple convulsions, with risk of severity associated with increasing age.
Our study had several limitations. A greater proportion of patients with P. knowlesi than other species were referred from district hospitals. Although introducing a potential bias, this was controlled for in analysis. The high proportion of referred patients with knowlesi malaria limited our ability to quantitate the true incidence of complications. We were also unable to assess all patients prior to commencement of treatment.
We confirm the public health importance of P. knowlesi in Sabah, with this species now the commonest cause of severe malaria at the state's largest hospital, and with a greater risk of severity than P. falciparum. With the marked reductions in falciparum and vivax malaria incidence in Sabah over the last 20 years [37] , loss of cross-species immunity may contribute to rising incidence and severity of disease from P. knowlesi [5] . The low case-fatality rate from severe knowlesi malaria in this series contrasts with the high case-fatality rate previously reported with the use of nonartemisinin therapies [7] . Early referral protocols and standardized (including prereferral) use of intravenous artesunate and oral ACT likely contributed to the low case-fatality rate from P. knowlesi and indeed all Plasmodium species in this series, and warrant wider implementation.
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